A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma
Allergic Bronchopulmonary Aspergilloses
About this trial
This is an interventional treatment trial for Allergic Bronchopulmonary Aspergilloses
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of ABPA as per the International Society for Human and Animal Mycology Working group criteria
- Treatment naïve
Exclusion Criteria:
- Failure to provide informed consent
- Enrollment in another trial of ABPA
- Pregnancy
- Creatinine more than or equal to 1.5 mg/dL
- Immunosuppressive states like chronic liver disease, chronic renal failure, cytotoxic therapy, uncontrolled diabetes mellitus and others
Sites / Locations
- Postgraduate Institute of Medical Education and Research
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Glucocorticoid group
Vitamin D plus Glucocorticoid group
Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months